Hyperthyroidism is a common and frequent disease in clinical practice, and ATD has been regarded as an effective way to treat hyperthyroidism for a long time. The application of ATD requires long period of treatment, at least 2 years in general. In clinical practice, a few of patients may suffer from serious side effect after taking ATD, including agranulocytosis and liver damage, which is the long-existing issue in the treatment of hyperthyroidism.
Recently, Dr. He Yayi, a member of Shi Bingyin team, published a research article titled “Association of HLA-B and HLADRB1 polymorphisms with antithyroid drug-induced agranulocytosis in a Han population from northern China”, on Scientific Reports. The research includes 29 cases of hyperthyroid patients suffering from agranulocytosis after taking ATD and 140 cases of normal granulocyte after taking ATD, and conducted HLA test. The result shows that HLA-B*27:05, HLA-B*38:02, and HLA-DRB1*08:03 are related to agranulocytosis caused by ATD, which means the patient carrying these genes may suffer from agranulocytosis after taking ATD. Regional and racial disparity are found in the susceptibility gene that causes agranulocytosis after taking ATD, but currently the research on this aspect is very limited. In this research, Han people from Northern China are targeted for the first time, which is valuable for discovering the genetic factor of ATD on causing agranulocytosis.
According to the research findings, it’s able to predict whether the patient may suffer from agranulocytosis by taking genetic test before treatment. For this group of patients,we will strengthen the monitoring to deal with the possible situations or take alternative treatment method if necessary. The research explains the mechanism of agranulocytosis caused by ATD from genetic angle and provides a new idea for accurate and personalized treatment.
Fig.: Relationship between genetic factor and agranulocytosis caused by ATD